- •
Transcatheter aortic valve replacement (TAVR) was initially only used in patients with severe symptomatic aortic stenosis and prohibitive risk for surgical aortic valve replacement (SAVR).
- •
Subsequently, this procedure was extended to patients with high and intermediate surgical risk and was reported as superior to SAVR in low-risk patients.
- •
Procedural outcomes have been improved owing to assessments by heart teams, the development of safer devices and delivery systems, and a better knowledge in
Transcatheter Aortic Valve Replacement: Procedure and Outcomes
Section snippets
Key points
Randomized trials of transcatheter aortic valve replacement versus surgical aortic valve replacement
After years of ex vivo testing and animal implantation of transcatheter heart valves (THVs), the first-in-human TAVR was performed by Cribier and colleagues1 in Rouen, France, in 2002. This first THV consisted of 3 bovine pericardial leaflets mounted within a tubular, slotted, stainless steel, balloon-expandable stent,1 and was implanted in a 57-year-old man with severe bicuspid AS, severely depressed left ventricle ejection fraction, and cardiogenic shock who was inoperable.1
After this first
Guidelines for the selection of transcatheter aortic valve replacement versus surgical aortic valve replacement
The strong body of evidence established by the randomized trials presented earlier have formed the basis of the current guidelines recommendations for the selection of TAVR versus SAVR (Fig. 1). In patients considered to have symptomatic severe AS and to be potential candidates for TAVR, the guidelines strongly recommend (class I) an evaluation of these patients by the heart team to confirm the indication of aortic valve replacement (AVR) and determine the optimal type of AVR: SAVR or TAVR (see
Type of Transcatheter Heart Valve
Historically, 2 main types of THV systems have been used: balloon-expandable (SAPIEN, SAPIEN XT, SAPIEN 3, Edwards Lifesciences; Irvine, CA) and self-expanding (CoreValve, EVOLUT R, EVOLUT PRO; Medtronic, Inc., Minneapolis, MN, USA) THVs (see Fig. 2; Fig. 3). Other catheter-based delivery systems have also been recently developed: inflatable rings (Direct Flow THV; Direct Flow Medical), and mechanically expandable THV (Lotus THV, Boston Scientific). During the TAVR evolution, the design and
Echocardiographic outcomes
Transvalvular pressure gradients and aortic valve areas are generally better with TAVR versus SAVR and within SAVR with self-expanding THVs compared with balloon-expandable THVs (Table 2).4,5,11,14 The superiority of self-expanding THVs seems to be related to the supra-annular position of the valve leaflets. This advantage is not present with the last iteration of the Edwards devices (SAPIEN 3), which have shown higher aortic mean gradient and less aortic valve area compared with surgical
All-Cause and Cardiovascular Mortality
A recent meta-analysis by Barbanti and colleagues40 of 37 studies and including 10,822 patients with high or intermediate risk undergoing transfemoral TAVR with new THV generations reported a 30-day all-cause and cardiovascular death rate of 2.2% (95% confidence interval [CI], 1.6%–2.8%) and 1.6% (95% CI, 0.9%–2.3%), respectively. These rates were even lower in low-risk patients,51,52 and were less than or equal to 0.5% in the recent randomized trials (Table 3).4,5 In high-risk patients and in
Future perspectives
The indications for TAVR are rapidly expanding. Recent registries of TAVR in patients with a bicuspid aortic valve have reported excellent results, which are as good as TAVR in patients with a tricuspid valve.73 However, TAVR is still contraindicated in patients with a bicuspid aortic valve and large aortic annulus and/or with concomitant aortopathy requiring surgical intervention.
The ongoing EARLY-TAVR (Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveiLance for Patients
Summary
TAVR has expanded rapidly since the first-in-human aortic THV implantation in 2002. In the near future, TAVR may become the treatment of choice for all patients with symptomatic severe AS who require intervention. Procedural outcomes have been improved owing to assessment by the heart teams, the development of safer devices and delivery systems, and better knowledge of the implantation techniques and patient management after the TAVR. However, long-term durability of THV remains to be confirmed
References (83)
- et al.
2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines
J Am Coll Cardiol
(2017) - et al.
Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery
J Am Coll Cardiol
(2014) - et al.
Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis
Lancet
(2016) - et al.
Outcomes, readmissions, and costs in transfemoral and alterative access transcatheter aortic valve replacement in the US Medicare population
J Thorac Cardiovasc Surg
(2017) - et al.
Multidetector computed tomography in transcatheter aortic valve implantation
JACC Cardiovasc Imaging
(2011) - et al.
Computed tomography imaging in the context of transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR): an expert consensus document of the Society of Cardiovascular Computed Tomography
J Cardiovasc Comput Tomogr
(2019) - et al.
Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients: initial human experience
J Am Coll Cardiol
(2014) - et al.
Transcarotid transcatheter aortic valve replacement: feasibility and safety
JACC Cardiovasc Interv
(2016) - et al.
2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American heart association task force on practice guidelines
J Am Coll Cardiol
(2014) - et al.
Transfemoral aortic valve replacement with the Edwards SAPIEN and Edwards SAPIEN XT prosthesis using exclusively local anesthesia and fluoroscopic guidance: feasibility and 30-day outcomes
JACC Cardiovasc Interv
(2012)
Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis
JACC Cardiovasc Interv
Transcatheter aortic valve implantation: review of the nature, management, and avoidance of procedural complications
JACC Cardiovasc Interv
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document
J Am Coll Cardiol
Annular rupture during transcatheter aortic valve replacement: classification, pathophysiology, diagnostics, treatment approaches, and prevention
JACC Cardiovasc Interv
Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI
J Am Coll Cardiol
Transcatheter aortic valve replacement with new-generation devices: a systematic review and meta-analysis
Int J Cardiol
Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation
JACC Cardiovasc Interv
Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome
J Am Coll Cardiol
Paravalvular regurgitation after transcatheter aortic valve replacement: is the problem solved?
Interv Cardiol Clin
Evaluation and management of paravalvular aortic regurgitation after transcatheter aortic valve replacement
J Am Coll Cardiol
Impact of paravalvular aortic regurgitation after transcatheter aortic valve implantation on survival
Int J Cardiol
Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme
JACC Cardiovasc Imaging
Cardiovascular magnetic resonance to evaluate aortic regurgitation after transcatheter aortic valve replacement
J Am Coll Cardiol
Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial
J Am Coll Cardiol
Transcatheter aortic valve replacement in low-risk patients: one-year results from the LRT trial
JACC Cardiovasc Interv
Protection against cerebral embolism during transcatheter aortic valve replacement
J Am Coll Cardiol
Clinical impact of baseline right bundle branch block in patients undergoing transcatheter aortic valve replacement
JACC Cardiovasc Interv
Predictors of advanced conduction disturbances requiring a late (>/=48 H) permanent pacemaker following transcatheter aortic valve replacement
JACC Cardiovasc Interv
Diagnosis of infective endocarditis after TAVR: value of a multimodality imaging approach
JACC Cardiovasc Imaging
Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications
J Am Coll Cardiol
Bioprosthetic valve thrombosis
J Am Coll Cardiol
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Lancet
Systematic CT methodology for the evaluation of subclinical leaflet thrombosis
JACC Cardiovasc Imaging
Valve-in-valve procedure in failed transcatheter aortic valves
JACC Cardiovasc Imaging
Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis
J Am Coll Cardiol
5-Year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients
J Am Coll Cardiol
Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description
Circulation
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Eur Heart J
Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients
N Engl J Med
Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients
N Engl J Med
Rapid adoption of transcatheter aortic valve replacement in intermediate- and high-risk patients to treat severe aortic valve stenosis
J Thorac Dis
Cited by (6)
Evolution of technology in replacement of heart valves: Transcatheter aortic valves, a revolution for management of valvular heart diseases
2021, Health Policy and TechnologyCitation Excerpt :New technology of Transcatheter Aortic Valve Implantation (TAVI, hereafter) is a less invasive medical technique based on a percutaneous valve implantation [47,50,54]. TAVI is an emerging technology, started in 2002, that is becoming more and more a routinely performed technique applied in cardiology to treat AS [24,42,45,52,53] Sedeek et al. [57] argue that TAVI is comparable to SAVR in terms of short- and medium-term mortality, and neurologic events in low surgical risk patients. Ando et al. [1] find out that TAVI has a significantly lower composite of all-cause mortality and lower disabling/major stroke at 1 year compared to SAVR in low-to-intermediate surgical risk cohort.
NUMERICAL INVESTIGATION OF THE VALVE MODEL FOR PRIMARY SUTURELESS IMPLANTATION
2023, Complex Issues of Cardiovascular DiseasesThe application of 3D printing in preoperative planning for transcatheter aortic valve replacement: a systematic review
2022, BioMedical Engineering OnlineMechanism of vascular injury in transcatheter Aortic Valve replacement
2021, Sovremennye Tehnologii v Medicine
Disclosure: Dr E. Salaun has nothing to disclose. Dr P. Pibarot received research grants from Edwards Lifesciences and Medtronic for echo corelab analyses in transcatheter aortic valve replacement. Dr J. Rodés-Cabau has received institutional research grants from Edwards Lifesciences.